Abstract
Erectile dysfunction (ED) is a common medical condition that has a negative impact on men and their partners. The field has revolutionised over the last two decades and more treatment options are available now for the treatment of ED than ever before. Among available treatment options, the most commonly prescribed therapies are oral phosphodiesterase type 5 (PDE5) inhibitors. The first drug in this class, sildenafil citrate, generally provides patients and their partners with efficacious, safe, and discreet treatment that rapidly has become the first-line treatment option. Its successful introduction into clinical practice was soon followed by the launch of two other PDE5 inhibitors: tadalafil and vardenafil. The existence of these drugs has resulted in an increase in their marketing. However, the abundance of choices made the question “which PDE-5 inhibitor?” relevant for clinicians, patients and their partners. It is widely accepted that there are no significant differences in their safety and efficacy, a fact that has led to the initiation of studies aiming to evaluate them regarding patient preference. Nevertheless, the results are rather conflicting. Also a significant percentage of men initiating treatment switch between inhibitors or discontinue therapy. This article examines the peer-reviewed published data addressing patient ’ s preference and adherence to ED treatment with PDE5 inhibitors. It also examines strategies to improve compliance and satisfaction with treatment.
Keywords: PDE5 inhibitors, preference, adherence, cost, treatment optimization, education, treatment expectations
Current Pharmaceutical Design
Title: Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment
Volume: 15 Issue: 30
Author(s): T. F. Al-Shaiji and G. B. Brock
Affiliation:
Keywords: PDE5 inhibitors, preference, adherence, cost, treatment optimization, education, treatment expectations
Abstract: Erectile dysfunction (ED) is a common medical condition that has a negative impact on men and their partners. The field has revolutionised over the last two decades and more treatment options are available now for the treatment of ED than ever before. Among available treatment options, the most commonly prescribed therapies are oral phosphodiesterase type 5 (PDE5) inhibitors. The first drug in this class, sildenafil citrate, generally provides patients and their partners with efficacious, safe, and discreet treatment that rapidly has become the first-line treatment option. Its successful introduction into clinical practice was soon followed by the launch of two other PDE5 inhibitors: tadalafil and vardenafil. The existence of these drugs has resulted in an increase in their marketing. However, the abundance of choices made the question “which PDE-5 inhibitor?” relevant for clinicians, patients and their partners. It is widely accepted that there are no significant differences in their safety and efficacy, a fact that has led to the initiation of studies aiming to evaluate them regarding patient preference. Nevertheless, the results are rather conflicting. Also a significant percentage of men initiating treatment switch between inhibitors or discontinue therapy. This article examines the peer-reviewed published data addressing patient ’ s preference and adherence to ED treatment with PDE5 inhibitors. It also examines strategies to improve compliance and satisfaction with treatment.
Export Options
About this article
Cite this article as:
Al-Shaiji F. T. and Brock B. G., Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789206944
DOI https://dx.doi.org/10.2174/138161209789206944 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
Current Molecular Medicine Challenges for the Treatment of Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Immunosuppressive and Antiviral Treatment of Inflammatory Cardiomyopathy
Recent Patents on Cardiovascular Drug Discovery Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews Fenofibrate: A New Treatment for Diabetic Retinopathy. Molecular Mechanisms and Future Perspectives
Current Medicinal Chemistry Proteomic Analysis of Liver Diseases: Molecular Mechanisms and Biomarker Discovery
Mini-Reviews in Medicinal Chemistry Influence of Glutathione on the Bioactivity of Subcutaneously or Orally Administered Insulin to Rats
Protein & Peptide Letters Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Current Diabetes Reviews Transmucosal Delivery of Metformin- A Comprehensive Study
Current Drug Delivery Recent Studies on Neural Tube Defects in Embryos of Diabetic Pregnancy: An Overview
Current Medicinal Chemistry Is Impaired Flow-Mediated Dilatation of the Brachial Artery a Cardiovascular Risk Factor?
Current Vascular Pharmacology Association of PAF and its Metabolic Enzymes with GGT and the Fatty Liver Index in Healthy Volunteers
Current Vascular Pharmacology Genus Salacia: Chemical Composition, Antidiabetic Effect and other Bioactivities
The Natural Products Journal Computational Insights into the Role of Glutathione in Oxidative Stress
Current Neurovascular Research Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adult Stem Cells and the Clinical Arena: Are we Able to Widely Use this Therapy in Patients with Chronic Limbs Arteriopathy and Ischemic Ulcers without Possibility of Revascularization?
Cardiovascular & Hematological Agents in Medicinal Chemistry Hypertension in Egypt: A Systematic Review
Current Hypertension Reviews